Disease‐modifying therapies provide new horizons for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PN) to slow neuropathic progression. Initiating treatment at the earliest time requires biomarkers reflecting both small‐ and large‐fiber degeneration in carriers.

中文翻译：

---

遗传性转甲状腺素 Ala117Ser 淀粉样变性伴多发性神经病临床前携带者神经完整性的早期变化

疾病修饰疗法为遗传性转甲状腺素蛋白淀粉样变性伴多发性神经病 (ATTRv-PN) 提供了新的视野，以减缓神经病变的进展。尽早开始治疗需要生物标志物反映携带者的小纤维和大纤维变性。